Radius Health Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View analyst ratings for Radius Health or view top-rated stocks.

Wall Street analysts have given Radius Health a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Radius Health wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Radius Health is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Radius Health.

Radius Health, Inc. (NASDAQ:RDUS) posted its earnings results on Friday, May, 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $56.26 million for the quarter, compared to analyst estimates of $59.28 million.
View Radius Health's earnings history.

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RDUS stock has increased by 18.3% and is now trading at $19.00.
View which stocks have been most impacted by COVID-19.

8 brokers have issued twelve-month price targets for Radius Health's shares. Their forecasts range from $14.00 to $33.00. On average, they anticipate Radius Health's share price to reach $25.13 in the next year. This suggests a possible upside of 32.2% from the stock's current price.
View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts.

Some companies that are related to Radius Health include Intra-Cellular Therapies (ITCI), Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Cassava Sciences (SAVA), Nektar Therapeutics (NKTR), PTC Therapeutics (PTCT), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), Dicerna Pharmaceuticals (DRNA), Amicus Therapeutics (FOLD), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX) and IGM Biosciences (IGMS).
View all of RDUS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.26%), Artisan Partners Limited Partnership (3.41%), Camber Capital Management LP (3.18%), Geode Capital Management LLC (1.70%), Northern Trust Corp (1.12%) and Rubric Capital Management LP (0.95%). Company insiders that own Radius Health stock include Anthony Rosenberg, Growth N V Biotech, James George Chopas and Target N V Biotech.
View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., BlackRock Inc., Camber Capital Management LP, Renaissance Technologies LLC, Clearline Capital LP, Rubric Capital Management LP, Russell Investments Group Ltd., and Credit Suisse AG.
View insider buying and selling activity for Radius Health or view top insider-selling stocks.

RDUS stock was acquired by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Arrowstreet Capital Limited Partnership, Hennion & Walsh Asset Management Inc., Federated Hermes Inc., Globeflex Capital L P, Voloridge Investment Management LLC, Citigroup Inc., and Millennium Management LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, and Target N V Biotech.
View insider buying and selling activity for Radius Health or or view top insider-buying stocks.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDUS stock can currently be purchased for approximately $19.00.

Radius Health has a market capitalization of $897.62 million and generates $238.65 million in revenue each year. The biopharmaceutical company earns $-109,210,000.00 in net income (profit) each year or ($2.35) on an earnings per share basis.

Radius Health employs 310 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]